ME01222B - Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera - Google Patents

Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera

Info

Publication number
ME01222B
ME01222B MEP-2011-128A MEP12811A ME01222B ME 01222 B ME01222 B ME 01222B ME P12811 A MEP12811 A ME P12811A ME 01222 B ME01222 B ME 01222B
Authority
ME
Montenegro
Prior art keywords
sulfonamide compound
cancer
treatment
combinational use
novel combinational
Prior art date
Application number
MEP-2011-128A
Other languages
English (en)
Inventor
Takashi Tsukuba Res Lab Eisai Co Ltd Owa
Yoichi Tsukuba Res Lab Eisai Co Ltd Ozawa
Taro Tsukuba Res Lab Eisai Co Ltd Semba
T Tsukuba Res Lab Eisai Co Ltd Wakabayashi
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of ME01222B publication Critical patent/ME01222B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Farmaceutsko jedinjenje koje uključuje jedinjenje sulfonamida u kombinaciji sa supstancom koja ima EGF inhibitorsku akti vnost, gdje je jedinjenje sulfonamida: N-(3-hloro-1Hindole- 7-yl)-4-sulfamoylbenzensulfonamid,N-(3-cijano-4-metil-1H-indole-7-yl)-3-cijanobenzensulfonamid, ili farmaceutsko prihvatljivu so istog ili njegov rastvor, i gdje je supstanca koja ima EGF inhibitorsku aktivnost gefitinib, erlotinib ili cetuksimab. Patent sadrži još 9 patentnih zahtjeva.
MEP-2011-128A 2005-02-28 2006-02-28 Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera ME01222B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005054111 2005-02-28
PCT/JP2006/304218 WO2006090930A1 (ja) 2005-02-28 2006-02-28 スルホンアミド化合物の新規併用
EP06715261A EP1859793B1 (en) 2005-02-28 2006-02-28 Novel combinational use of a sulfonamide compound in the treatment of cancer

Publications (1)

Publication Number Publication Date
ME01222B true ME01222B (me) 2013-06-20

Family

ID=36927547

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2011-128A ME01222B (me) 2005-02-28 2006-02-28 Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera

Country Status (18)

Country Link
US (1) US20090047278A1 (me)
EP (1) EP1859793B1 (me)
JP (1) JPWO2006090930A1 (me)
KR (1) KR20070108270A (me)
CN (1) CN101163468A (me)
AU (1) AU2006217692A1 (me)
CA (1) CA2599115A1 (me)
CY (1) CY1111579T1 (me)
DE (1) DE602006021401D1 (me)
DK (1) DK1859793T3 (me)
ES (1) ES2362898T3 (me)
HR (1) HRP20110349T1 (me)
ME (1) ME01222B (me)
PL (1) PL1859793T3 (me)
PT (1) PT1859793E (me)
RS (1) RS51821B (me)
SI (1) SI1859793T1 (me)
WO (1) WO2006090930A1 (me)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
JPWO2004080462A1 (ja) * 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
ATE428421T1 (de) * 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
EP1859804B1 (en) * 2005-02-10 2016-12-07 Oncolys BioPharma, Inc. Anticancer agent combination therapy
US20090047365A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
EP1938842A4 (en) * 2005-09-01 2013-01-09 Eisai R&D Man Co Ltd METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
WO2007052849A1 (ja) 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CN101443009A (zh) * 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
KR101472600B1 (ko) * 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
AU2008205847A1 (en) * 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CA2713930A1 (en) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
EP3730139B1 (en) 2008-06-17 2023-08-16 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
KR101434009B1 (ko) 2008-08-04 2014-08-25 와이어쓰 엘엘씨 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
KR101677790B1 (ko) 2010-06-25 2016-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
SI3524595T1 (sl) 2014-08-28 2022-10-28 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistosti in postopek njegove proizvodnje
WO2016136745A1 (ja) 2015-02-25 2016-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CU24558B1 (es) * 2017-11-28 2021-12-08 Ct Inmunologia Molecular Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados
US11807606B2 (en) 2018-01-25 2023-11-07 Dana-Farber Cancer Institute, Inc. Sulfonamide derivatives for protein degradation
AR114793A1 (es) 2018-04-18 2020-10-14 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2021151974A1 (en) 2020-01-28 2021-08-05 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Interfering with mrna splicing to enhance response to checkpoint immunotherapies.
US20230190707A1 (en) * 2020-05-15 2023-06-22 Fred Hutchinson Cancer Center Compositions and methods for enhancing cancer immunotherapy
CN113679720B (zh) * 2020-05-19 2024-09-27 苏中药业集团股份有限公司 一种取代丁烯酰胺联合铂类化合物的药物组合物及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPS5857710A (ja) 1981-09-30 1983-04-06 Matsushita Electric Works Ltd コイル
EP0183858B1 (de) * 1984-11-22 1988-09-14 Holsten-Brauerei AG Bier und Verfahren zu dessen Herstellung
IL80032A (en) * 1985-09-23 1992-07-15 Lilly Co Eli Anti-tumor phenyl-aminocarbonylsulfonamides,their preparation and pharmaceutical compositions containing them
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
DK0628639T3 (da) * 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
DK0673937T3 (da) * 1993-09-10 2004-03-22 Eisai Co Ltd Bicyclisk heterocyclisk sulfonamid og sulfonsyreesterderivater
JP3545461B2 (ja) 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
EP1110953B1 (en) 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JP2000247949A (ja) 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
YU13200A (sh) * 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
ATE440618T1 (de) * 2000-06-22 2009-09-15 Univ Iowa Res Found Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
SK14642003A3 (sk) * 2001-06-06 2004-12-01 Eli Lilly And Company Benzoylsulfónamidy a sulfonylbenzamidíny ako protinádorové činidlá
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
TWI281916B (en) 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
US20050119303A1 (en) * 2002-03-05 2005-06-02 Eisai Co., Ltd Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with an angiogenesis inhibitor
MY136840A (en) * 2002-09-19 2008-11-28 Schering Corp Pyrazolopyridines as cyclin dependent kinase inhibitors
JP3785390B2 (ja) 2002-09-24 2006-06-14 平野整機工業株式会社 自転車後輪駆動装置及び自転車
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
EP2364699A1 (en) * 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor

Also Published As

Publication number Publication date
KR20070108270A (ko) 2007-11-08
PT1859793E (pt) 2011-07-05
SI1859793T1 (sl) 2011-08-31
EP1859793A4 (en) 2008-07-23
CN101163468A (zh) 2008-04-16
HRP20110349T1 (hr) 2011-07-31
ES2362898T3 (es) 2011-07-14
RS51821B (en) 2012-02-29
AU2006217692A1 (en) 2006-08-31
CY1111579T1 (el) 2015-10-07
WO2006090930A1 (ja) 2006-08-31
US20090047278A1 (en) 2009-02-19
EP1859793B1 (en) 2011-04-20
JPWO2006090930A1 (ja) 2008-07-24
EP1859793A1 (en) 2007-11-28
PL1859793T3 (pl) 2011-09-30
DK1859793T3 (da) 2011-08-01
DE602006021401D1 (de) 2011-06-01
CA2599115A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
ME01222B (me) Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera
BRPI0411900A (pt) compostos antivirais e métodos
NO20063572L (no) Kinazolinditosylatsalt forbindelser
AU311847S (en) Pleated face mask
DE60218458D1 (de) Isochinolinon derivate als parp inhibitoren
EA200100678A1 (ru) N-уреидоалкил-пиперидины в качестве модуляторов активности рецепторов хемокинов
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
DE50310516D1 (de) Fredericamycin-derivate
CY1110061T1 (el) Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης
ATE441635T1 (de) 4-cyanopyrazol-3-carbonsäureamidderivate, herstellung und therapeutische anwendung davon
ATE428698T1 (de) Die aktivität von gamma-secretase blockierende malonamidderivate
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
NO20044388L (no) Derivater av N-[fenyl(piperidin-2yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutika
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
AU311848S (en) Pleated face mask
EA200602157A1 (ru) Новые производные тетрагидропиридотиофена
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
WO2004043362A3 (en) Acyl guanidine compounds and use thereof
ATE325135T1 (de) 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
CL2004000261A1 (es) Procedimiento para la eliminacion de virus en soluciones de fibrinogeno de aplicacion terapeutica.
ITMI20040954A1 (it) Derivati del 3,6-diazabiciclo 3.1.i.eptano ad attivita' analgesica
ATE427773T1 (de) Verwendung von n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-a1,3,4- xadiazol-2-yluphenyl)pyridin-3- sulphonamid in der tumortherapie
FI20011466A0 (fi) Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö